This study is a prospective single-arm clinical study, focusing on Epstein-Barr
virus-associated hemophagocytic lymphohistiocytosis and Chronic Active Epstein-Barr Virus
Infection with only and mainly B lymphocytes of EBV infection, to evaluate the clinical
efficacy of Rituximab in the treatment of EBV-HLH and CAEBV.